Four months after getting a promising readout on its lead drug in a Phase IIb study for irritable bowel syndrome, AstraZeneca-partnered Ardelyx reported another study win today, but investors zeroed in on a disturbing safety issue and ripped up the company’s shares soon after the release went out.

…read more

Source: UPDATED: AstraZeneca partner Ardelyx plunges after citing safety issue for lead drug


0 No comments